when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

GIP receptor · news · pharmadog

← back to GIP receptor

News · GIP receptor

52 stories

Aug 24, 26Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismfiercebiotech

Aug 20, 26Roche pours $750M into Oregon manufacturing plant as obesity push expandsbiospace

Aug 19, 26Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?biospace

Aug 13, 26Chutes & Ladders—Former Legend CEO lands at K2fiercebiotech

Aug 10, 26AstraZeneca partners with CSPC to build Chinese biologics manufacturing plantbiospace

Aug 5, 26Amgen’s MariTide stands alone after obesity cull while analysts seek more M&Abiospace

Aug 4, 26Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructurebiospace

Aug 4, 26Amgen drops early-stage obesity drug, upping pressure on MariTidefiercebiotech

Aug 4, 26Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearoutfiercebiotech

Jul 31, 26Lilly and Resilience invest $750M in diabetes and obesity drug device supplybiospace

Jul 28, 26Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage studybiospace

Jul 28, 26Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder winfiercebiotech

Jul 24, 26Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechbiospace

Jul 24, 26Roche cans one Carmot obesity asset as another shows best-in-class potentialbiospace

Jul 23, 26Lilly, with new data, to seek FDA approval of obesity drug retatrutidebiopharma dive

Jul 23, 26Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 databiospace

Jul 23, 26Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onbiospace

Jul 23, 26Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clearfiercebiotech

Jul 23, 26Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapiesfiercebiotech

Jun 29, 2610 clinical trials to watch in the second half of 2026biopharma dive

Jun 8, 26#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotendpoints

Apr 28, 26Boehringer dual-acting obesity shot hits mark in Phase 3 trialbiopharma dive

← prevpage 2 of 2next →